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Abstract
Here, we provide evidence that high ATP production by the mitochondrial ATP-synthase is a new therapeutic target for
anticancer therapy, especially for preventing tumor progression. More specifically, we isolated a subpopulation of ATP-high
cancer cells which are phenotypically aggressive and demonstrate increases in proliferation, stemness, anchorage-
independence, cell migration, invasion and multi-drug resistance, as well as high antioxidant capacity. Clinically, these
findings have important implications for understanding treatment failure and cancer cell dormancy. Using bioinformatic
analysis of patient samples, we defined a mitochondrial-related gene signature for metastasis, which features the gamma-
subunit of the mitochondrial ATP-synthase (ATP5F1C). The relationship between ATP5F1C protein expression and
metastasis was indeed confirmed by immunohistochemistry. Next, we used MDA-MB-231 cells as a model system to
functionally validate these findings. Importantly, ATP-high MDA-MB-231 cells showed a nearly fivefold increase in
metastatic capacity in vivo. Consistent with these observations, ATP-high cells overexpressed (i) components of
mitochondrial complexes I–V, including ATP5F1C, and (ii) markers associated with circulating tumor cells (CTCs) and
metastasis, such as EpCAM and VCAM1. Knockdown of ATP5F1C expression significantly reduced ATP-production,
anchorage-independent growth, and cell migration, as predicted. Similarly, therapeutic administration of the FDA-approved
drug, Bedaquiline, downregulated ATP5F1C expression in vitro and prevented spontaneous metastasis in vivo. In contrast,
Bedaquiline had no effect on the growth of non-tumorigenic mammary epithelial cells (MCF10A) or primary tumors in vivo.
Taken together, our results suggest that mitochondrial ATP depletion is a new therapeutic strategy for metastasis
prophylaxis, to avoid treatment failure. In summary, we conclude that mitochondrial ATP5F1C is a promising new
biomarker and molecular target for future drug development, for the prevention of metastatic disease progression.
Introduction
ATP is the universal bioenergetic “currency” of all living
cells and tissues, including microorganisms, such as pro-
karyotic bacteria and eukaryotic yeast(s) [1–3]
In eukaryotes, mitochondrial organelles function as the
“powerhouse” of the cell [4–7]. Mitochondria generate a
vast amount of ATP via the TCA cycle and oxidative
phosphorylation (OXPHOS), while glycolysis contributes a
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minor amount of ATP [8]. Conversely, mitochondrial dys-
function induces ATP depletion, resulting in autophagy,
apoptosis (programmed cell death), and/or necrosis [9].
Thus, we have proposed that ATP-depletion therapy may be
a viable strategy for targeting and eradicating even the
“fittest” cancer cells [10–13].
In MCF7 breast cancer cells, mitochondrial-driven
OXPHOS contributes to 80–90% of ATP production,
while glycolysis only contributes the remaining 10-20%,
under normoxic conditions [14, 15]. Therefore, like normal
cells, cancer cells are highly dependent on mitochondrial
ATP production [14, 16]. However, it still remains largely
unknown if ATP levels in cancer cells contribute to
“stemness” and cell cycle progression, as well as their
ability to undergo 3D anchorage-independent growth, a
characteristic feature of metastatic spread.
Here, we now show that the induction of ATP depletion
in MDA-MB-231 breast cancer cells with Bedaquiline, an
FDA-approved drug, was indeed sufficient to prevent
spontaneous metastasis in a xenograft model, without
affecting tumor growth, or inducing significant toxicity.
Moreover, we demonstrate that Bedaquiline specifically
targets ATP5F1C, the gamma-subunit of the mitochondrial
ATP-synthase. These findings are consistent with the idea
that ATP is a functional biomarker of metastasis.
Materials and methods
Bioinformatic analysis
Unbiased label-free proteomics, comparing 2D-monolayers
and 3D-mammospheres, was carried out, as previously
described, using MCF7 and T47D breast cancer cell lines
[17]. Informatics analysis was also performed using a variety
of publicly available of GEO DataSets (GSE36953;
GSE2034; GSE59000; and GSE55470), archived in the
NCBI database, related to 3D growth, primary tumors,
metastasis and circulating tumor cells (CTCs). Gene
expression profiling data was extracted from these GEO
DataSets. HeatMaps were generated with QIAGEN Omic-
Soft Suite Software. Volcano plots were produced by
examining the annotations present in OncoLand Metastatic
Cancer (QIAGEN OmicSoft Suite). In addition, we per-
formed functional “core analyses” using Ingenuity Pathway
Analysis Software (IPA; QIAGEN), on annotated genes.
Gene co-expression profiles were extracted from The
Metastatic Breast Cancer Project Provisional (2020), using
cBioPortal (https://www.cbioportal.org/); mRNA expression
profiling (RNA Seq V2 RSEM) was carried out via RNA-
sequencing of breast cancer tissue samples derived from 146
patients, with metastatic disease. See Supplemental Infor-
mation and related Figure Legends for specific details.
IHC staining with ATP5F1C antibodies
The study included 12 female patients with a diagnosis of
invasive breast carcinoma, treated at the University Hospital
of Pisa between 2010 and 2020. Among these, the primary
tumor and the corresponding axillary lymph nodal metastasis
were retrieved in five patients; distant metastasis alone was
retrieved in six patients (two bone metastases, two ovarian
metastases, one skin metastasis, one brain metastasis); the
primary tumor, the corresponding axillary lymph nodal
metastasis together with the skin and the liver metastases were
retrieved in 1 patient. All investigations were conducted
according to the principles expressed in the Declaration of
Helsinki; this study was approved by the local Ethical
Committee (Prot. n: 17770. Approval date: 28/10/2020).
Written consent was obtained from each participant. All
retrieved formalin-fixed, paraffin-embedded samples dis-
played enough tissue to conduct both analyses and storage.
Hematoxylin and eosin (H&E) stained slides were reviewed
by one pathologist with expertise in breast cancer (CS) and
one representative paraffin block was selected. Immunohis-
tochemistry (IHC) for ATP5F1C was carried out from each
paraffin block, applying the specific antibody (clone
2A1AA11, Mouse Monoclonal, Abcam; dilution: 1:100,
citrate buffer antigen retrieval: pH 6, 8 min; antibody incu-
bation time: 44min) in an automated immunostainer
(BenchMark Ultra, Ventana Medical Systems). ATP5F1C
positivity was expressed as intensity of cytoplasmic staining
(faint; weak; moderate; strong). All stained sections were
evaluated independently and blindly by two pathologists with
expertise in breast cancer (CS and AGN). Discrepancies were
resolved via consensus on a double-headed microscope.
Kaplan–Meier (K–M) analysis
To perform K–M analysis on ATP5F1C, we used an open-
access online survival analysis tool to interrogate publicly
available microarray data from up to 3951 breast cancer
patients [18]. For this purpose, we primarily analyzed data
from ER(+) patients. Biased array data were excluded from
the analysis. This allowed us to identify ATP5F1C (also
known as ATP5C1), as a significant prognostic marker.
Hazard-ratios were calculated, at the best auto-selected cut-
off, and p-values were calculated using the Log-rank test
and plotted in R. K–M curves were generated online using
the K–M plotter (as high-resolution TIFF files), using uni-
variate analysis: https://kmplot.com/analysis/index.php?p=
service&cancer=breast. This approach allowed us to
directly perform in silico validation of ATP5F1C as a
marker of tumor recurrence (relapse-free survival) and dis-
tant metastasis (distant metastasis-free survival). The latest
2020 version of the database was utilized for all these
analyses.
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Reagents and model cell lines
BioTracker ATP-Red 1 (#SCT045) was obtained com-
mercially from Merk-Millipore, Inc. BioTracker green
fluorescent probes for cystine uptake (#SCT047), gamma-
glutamyl-transferase activity (GGT; #SCT028), plur-
ipotent stem cells (#SCT029), hypoxia (#SCT033) and
beta-galactosidase (#SCT025), were all obtained from
either Sigma Aldrich or Merk-Millipore, Inc. 4-OH-
Tamoxifen, Gemcitabine, DPI (Diphenyleneiodonium
chloride), Doxycycline and Palbociclib were all purchased
from Sigma-Aldrich, Inc. CSC markers were purchased,
as follows: (i) CD44 antibodies (APC Mouse Anti-Human
CD44, BD Pharmingen, Inc.) and (ii) AldeRed™ reagent
dye from ALDH Detection Assay (Merk-Millipore, Inc.)
for measuring ALDH activity. The Muse® Autophagy
LC3-Antibody Based Kit (Luminex, Corp.) was employed
for measuring the Autophagy Induction ratio. Reagents
for profiling the intracellular levels of metabolites (ATP,
GSH, NADH and NADPH) after cell lysis, were all
obtained from Promega, Inc. ER(+) [MCF7 and T47D]
and triple-negative [MDA-MB-231 and MDA-MB-468]
human breast cancer cell lines were obtained from the
American Type Culture Collection (ATCC). MCF-10A
cells, a non-tumourigenic human breast epithelial cell
line, were also obtained from ATCC. All cell lines used
were tested using the MycoFluor™ Mycoplasma Detec-
tion Kit (Thermo Scientific, Inc.), confirming that they
were mycoplasma-free. MCF7, MDA-MB-231, and
MDA-MB-48 cells were cultured in DMEM (High Glu-
cose) supplemented with 10% Fetal Bovine Serum (FBS,
Sigma Aldrich), 2 mM Glutamax (Gibco, Life Technolo-
gies, Waltham, MA, USA), and 1% penicillin/strepto-
mycin (Gibco, Life Technologies). DMEM/F12 (Sigma
Aldrich) supplemented with 10% FBS, 2 mM Glutamax,
and 1% penicillin/streptomycin was used to culture T47D
cells. Analysis and treatments were performed in the
above-mentioned media. The MCF10A cell line was
maintained in a mammary epithelial cell growth medium
(MEGM; Lonza, Basel, Switzerland) supplemented with
0.4% Bovine pituitary extract, 0.1% insulin, 0.1% hEGF,
0.1% Hydrocortisone, 0.1% GA-1000, and 100 ng/mL of
cholera toxin. All cell lines were cultured at 37 °C in 5%
CO2 in a humidified atmosphere.
Cell sorting and flow cytometry after vital staining
with BioTracker ATP-red 1
Human breast cancer cell lines were first grown either as a
2D monolayer or as 3D-mammospheres. Then, they were
stained with 10 µM of BioTracker ATP-Red 1 for at least
30 min. The cells were washed twice with Dulbecco’s
phosphate-buffered saline (DPBS; Gibco, Life
Technologies), collected and dissociated into a single-cell
suspension, using a 25-g needle syringe and a 40 µm cell
strainer (Fisher Scientific, Inc.), prior to analysis or sorting
by flow-cytometry with the SONY SH800 Cell Sorter [19].
Briefly, ATP-high and ATP-low subpopulations of cells
were isolated after vital staining with the probe ATP-Red 1.
The ATP-high and ATP-low cell subpopulations were
selected by gating, within the ATP-Red 1 signal (Excitation:
510 nm; Emission: 570 nm). Only cells with the least
(bottom 5 or 10%) or the most (top 5 or 10%) signal were
collected. Also, a population between the bottom and the
top populations was sorted (bulk 5%). The cells outside the
gates were discarded during sorting, due to the gate settings.
However, such settings are required, to ensure high purity
during sorting. Data were analyzed with FlowJo
10.1 software.
Fluorescence imaging
After 24 h post-sorting, all the cell lines seeded in black 96-
well plates were stained with 16 µM of Hoescht 33342
(Thermo Fischer, Inc.) and 10 µM of BioTracker ATP-Red
1. Then, the cells were washed twice with DPBS and the
images were acquired at 20× magnification, using the
EVOS FL 2 automated microscope.
Flow cytometry after staining with BioTracker
fluorescent probes
MCF7 cells first grown as a 2D-monolayer, were stained
with BioTracker fluorescent probes for cystine uptake
(#SCT047), gamma-glutamyl-transferase activity (GGT;
#SCT028), pluripotent stem cells (#SCT029), hypoxia
(#SCT033), and beta-galactosidase (#SCT025), respec-
tively, following the concentrations and incubation times,
as described by the supplier. Then, the cells were washed
twice in PBS, collected and dissociated into a single-cell
suspension, using a 40 µm cell strainer. The cells
were sorted using the SONY SH800 Cell Sorter. Briefly,
probe-high and probe-low subpopulations of cells were
isolated. Only cells with the least (bottom 5%) or the
most (top 5%) signal were collected. The cells outside the
gates were discarded during sorting, due to the gate
settings.
ATP assay using Cell-Titer-Glo
Cell-Titer-Glo (#G7570) was obtained from Promega,
Inc., and was used according to the manufacturer’s
recommendations, to measure ATP levels in lysed cells.
Cell-Titer-Glo is a luciferase-based assay system. Lumi-
nescence content was evaluated using the Varioskan™
LUX plate reader.
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ATP assay using BioTracker ATP-red 1
Cells were stained with BioTracker ATP-Red 1 after var-
ious treatments. After 30 min of incubation, the cells were
washed twice with DPBS, collected and dissociated into a
single-cell suspension with a 40 µm cell strainer. The cells
were analyzed using the Attune NxT Flow Cytometer.
Means of the signal (at 570 nm) were compared.
3D anchorage-independent growth assay
A single-cell suspension was prepared using enzymatic, and
manual disaggregation (25-g needle). Then, cells were plated
at a density of 500 cells/cm2 in mammosphere medium
(DMEM-F12+ 1× B-27 Plus Supplement+ 20 ng/ml EGF
+ Pen/Strep) under non-adherent conditions, in culture dishes
precoated with (2-hydroxyethylmethacrylate) (poly-HEMA,
Sigma Aldrich Inc.), called “mammosphere plates.” Cells
were grown for 5 days and maintained in a humidified
incubator at 37 °C. After 5 days of culture, 3D-
mammospheres >50 μm were counted using an eyepiece
(“graticule”), and the percentage of cells plated which formed
spheres was calculated and is referred to as percent mam-
mosphere formation, and was normalized to one (1= 100%
mammosphere formation efficiency (MFE)). 3D MFE was
analyzed in both the ATP-low and ATP-high subpopulations
of cells. All 3D mammosphere experiments were performed
in triplicate, at least three times independently.
3D spheroid formation assay
3D Spheroids were generated following the application note
by Thermo Fisher (https://assets.thermofisher.com/TFS-
Assets/BID/Application-Notes/mcf7-spheroids-serum-free-a
pplication-note). Cells were seeded in DMEM/F-12, HEPES,
no phenol red, and 1× B-27 Plus Supplement, 10 ng/mL of
HS bFGF (Gibco Life Technologies) for a total volume of
0.2mL/well and a total of 500 cells/well. The plate was then
centrifuged at 120 × g for 5 min before being placed in a
37 °C, 5% CO2 incubator. The spheroids were incubated for
10 days without changing the media before analysis, but the
spheroids were observed to form overnight after seeding.
MCF7 cells harboring an ATP-binding protein
biosensor
Tempo-ATP-MCF7 cells, recombinantly over-expressing a
cytosolic fluorescent protein ATP-biosensor, were custom-
generated by Tempo-Bioscience, Inc. (San Francisco, CA,
USA), using a puromycin-resistance marker for cell selec-
tion. This protein-based fluorescent ATP-biosensor has an
excitation wavelength of 517–519 nm and an emission of




HMGMSGS) [20] fused in-frame with a GFP-like fluor-
escent reporter protein.
shRNA lentiviral transduction
Lentiviral plasmids, packaging cells, and reagents were
purchased from Genecopoeia. Forty-eight hours after
seeding, 293Ta packaging cells were transfected with len-
tiviral vectors encoding an shRNA clone set of three con-
structs against all three variants for human ATP5F1C, in a
lentiviral psi-LVRInU6TGP vector, with an inducible U6
promoter, CMV promoter-TetR-SV40 promoter-eGFP-
IRES-puromycin. A scrambled control psi-LVRInU6TGP
vector (sh-Control) was transfected in parallel. Two days
post-transfection, the lentivirus-containing culture medium
was passed through a 0.45 µm filter and added to the target
cells (MDA-MB-231), in the presence of 5 µg/ml Poly-
brene. Infected cells were selected, with a concentration of
1.5 µg/ml of puromycin.
Western blotting
Cells were lysed in RIPA buffer (Sigma Aldrich, Inc.) con-
taining one tablet of CompleteTM inhibitor mix (Roche
Applied Science, Indianapolis) and one tablet of PhosSTOP™
phosphate inhibitors per 10mL of buffer and loaded onto
SDS-polyacrylamide gels. The gels were transferred to 0.2 µm
nitrocellulose membranes, using the Trans-Blot Turbo
Transfer System (Bio-Rad, Inc.) Membranes were incubated
with the respective primary antibodies diluted in Tris-buffered
saline, 0.1% Tween 20 (Sigma Aldrich, Inc.) and 5% bovine
serum albumin (BSA; Sigma Aldrich Inc.) (TBST), and
incubated overnight at 4 °C. Then, the blots were washed and
incubated with appropriate secondary antibodies and detected
using Super Signal West Pico Chemiluminescent Substrate
(Thermo Scientific, Inc.), using the G-Box (Syngene, Inc).
Antibodies and their dilutions used for Western blot analysis
were as follows: mouse anti-ATP5F1C 1:500, mouse anti-
HSP60 1:1000, mouse anti-HIF-1α 1:500, mouse anti-human
total OXPHOS cocktail 1:1000, mouse anti-Ep-CAM 1:500,
mouse anti-VCAM-1 1:500, mouse anti-β-tubulin 1:2000,
mouse anti-β-actin 1:10,000, rabbit anti-PARP 1:1000, rabbit
anti-p21 1:1000, rabbit anti-SQSTM1/p62 1:1000, and mouse
anti-Vinculin 1:1000. The resulting immunoblot images were
acquired using GeneSys Software (Syngene, Inc.)
Metabolic flux analysis with the Seahorse XFe96
Real-time oxygen consumption rates (OCRs) and extra-
cellular acidification rates (ECARs) rates were determined
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using the Seahorse Extracellular Flux (XFe96) analyzer
(Seahorse Bioscience, USA) [21, 22]. Briefly, 3 × 104 cells
per well were seeded into XFe96 well cell culture plates
after sorting and incubated for 12 h to allow cell attachment.
After 24 h of incubation, cells were washed in pre-warmed
XF assay media (or for OCR measurement, XF assay media
supplemented with 10 mM glucose, 1 mM Pyruvate, 2 mM
L-glutamine, and adjusted at 7.4 pH). Cells were then
maintained in 175 μL/well of XF assay media at 37 °C, in a
non-CO2 incubator for 1 h. During the incubation time, we
loaded 25 μL of 80 mM glucose, 9 μM oligomycin, and 1M
2-deoxyglucose (for ECAR measurement) or 10 μM oligo-
mycin, 9 μM FCCP, 10 μM rotenone, 10 μM antimycin A
(for OCR measurement), in XF assay media into the
injection ports in the XFe96 sensor cartridge. Measurements
were normalized by Hoechst 33342 content and/or protein
content (SRB assay). Data sets were analyzed using
XFe96 software and GraphPad Prism software, using one-
way ANOVA and Student’s t test calculations. All experi-
ments were performed in quintuplicate, three times
independently.
Cell cycle analysis by fluorescence-activated cell
sorting (FACS)
We performed cell-cycle analysis on the ATP-high and
ATP-low cell subpopulations, by FACS analysis using the
Attune NxT Flow Cytometer. Briefly, after trypsinization,
the resuspended cells were incubated with propidium
iodide, as per the manufacturer’s recommendations (Cell
Cycle Kit; Merck Millipore, Inc.). We analyzed 25,000
events per condition. Gated cells were categorized into cell-
cycle stages.
Cell migration and invasion assays
Briefly, 3.5 × 104 cells in 0.5 ml of serum-free DMEM
with 0.1% BSA were added to the wells of 8-μm pore,
non-coated membrane modified Boyden chambers
(Transwells). The lower chambers contained 10% FBS in
DMEM to serve as a chemo-attractant. Cells were incu-
bated at 37 °C and allowed to migrate throughout the
course of 16 h. Noninvasive cells were removed from the
upper surface of the membrane by scrubbing with cotton
swabs. Chambers were stained in 0.5% crystal violet
diluted in 100% methanol for 30–60 min, rinsed in water
and examined under a bright-field microscope. Values for
invasion and migration were obtained by counting five
fields per membrane (20× objective) and represent the
average of three independent experiments. Note that
Transwells, precoated with extracellular matrix (namely
Matrigel), were used to measure aggressive cell invasion
and prevent simple cell migration.
Flow cytometry analysis with LC3 antibodies
The Autophagy Induction ratio was calculated using an
autophagy LC3-antibody-based Kit for the Guava® Muse®
Cell Analyzer by Luminex. Totally, 5 × 104 MDA-MB-231
cells were treated with Bedaquiline (10 µM) or vehicle
alone, for 48, 72, and 120 h, and then subjected to analysis
by flow cytometry, following the procedure as described in
the kit protocol.
Metastasis assays
The chick embryo metastasis assay was performed by
INOVOTION (Société: 811310127), La Tronche-France.
According to the French legislation, no ethical approval is
needed for scientific experimentations using oviparous
embryos (decree n° 2013-118, February 1, 2013; art. R-214-
88). Animal studies were performed under animal experi-
mentation permits N° 381029 and B3851610001 to Jean
Viallet (INOVOTION). Fertilized White Leghorn eggs were
incubated at 37.5 °C with 50% relative humidity for 9 days.
Greater than 20 eggs were processed for each experimental
condition. At that moment (E9), the chorioallantoic mem-
brane (CAM) was dropped down by drilling a small hole
through the eggshell into the air sac, and a 1 cm2 window
was cut in the eggshell above the CAM. The MDA-MB-231
tumor cell line was cultivated in DMEM medium supple-
mented with 10% FBS and 1% penicillin/streptomycin. On
day E9, cells were detached with trypsin, washed with
complete medium, and suspended in graft medium. After
ATP-based cell sorting by flow-cytometry with BioTracker
ATP-Red 1, an inoculum of 30,000 cells was added onto the
CAM of each egg (E9) and then eggs were randomized into
groups. On day E18, a 1 cm2 portion of the lower CAM was
collected to evaluate the number of metastatic cells in
10 samples per group (N= 10). Genomic DNA was
extracted from the CAM (commercial kit) and analyzed by
qPCR with specific primers for Human Alu sequences.
Calculation of Cq for each sample, mean Cq and relative
amounts of metastases for each group are directly managed
by the Bio-Rad® CFX Maestro software. Non-injected eggs
were also evaluated in parallel, as a negative control for
specificity. A one-way ANOVA analysis with post-tests
was performed on all the data.
Tumor growth, metastasis, and embryo toxicity
assays
Xenograft assays were carried out by INOVOTION (Soci-
été: 811310127), La Tronche-France, essentially as we
previously described, without any major modifications
[23, 24]. Fertilized White Leghorn eggs were incubated at
37.5 °C with 50% relative humidity for 9 days. At that
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moment (E9), the CAM was dropped down by drilling a
small hole through the eggshell into the air sac, and a 1 cm2
window was cut in the eggshell above the CAM. The
MDA-MB-231 tumor cell line was cultivated in DMEM
medium supplemented with 10% FBS and 1% penicillin/
streptomycin. On day E9, cells were detached with trypsin,
washed with complete medium, and suspended in graft
medium. An inoculum of 1 × 106 MDA-MB-231 cells was
added onto the CAM of each egg (E9) and then eggs were
randomized into groups. On day E10, tumors were detect-
able, and they were then treated daily for 8 days with
vehicle alone (1% DMSO in PBS) or with three different
dosages of Bedaquiline. At day 18 (E18), the upper portion
of the CAM was removed from each egg, washed in
PBS and then directly transferred to paraformaldehyde
(fixation for 48 h) and weighed. For tumor growth assays, at
least 14 tumor samples were collected and analyzed per
group (N ≥ 14). On day E18, a 1 cm2 portion of the lower
CAM was collected to evaluate the number of metastatic
cells in at least seven samples per group (N ≥ 7). Genomic
DNA was extracted from the CAM (commercial kit) and
analyzed by qPCR with specific primers for Human Alu
sequences. Calculation of Cq for each sample, mean Cq and
relative amounts of metastases for each group are directly
managed by the Bio-Rad® CFX Maestro software. A one-
way ANOVA analysis with post-tests was performed on all
the data. Before each administration, the treatment toler-
ability was evaluated by scoring the number of live and
dead embryos.
Statistical analysis
All analyses were performed with GraphPad Prism 7. Data
were represented as mean ± SD (or ±SEM where indicated).
All experiments were conducted at least three times inde-
pendently, with 3 or more technical replicates for each
experimental condition tested (unless stated otherwise, e.g.,
when representative data is shown). Statistically significant
differences were determined using the Student’s t test or the
analysis of variance (ANOVA) test. For the comparison
among multiple groups, one-way ANOVA was used to
determine statistical significance. p < 0.05 was considered
significant.
Results
Bioinformatic analysis of ATP synthesis and cancer
metastasis: Importance of ATP5F1C, the gamma-
subunit of the mitochondrial ATP-synthase
Here, we have begun to test the hypothesis that mitochon-
drial ATP synthesis is a key determinant of 3D anchorage-
independent growth and metastasis, using a bioinformatics
approach. More specifically, we defined a mitochondrial-
related gene signature for metastasis, which features the
gamma-subunit of the mitochondrial ATP-synthase
(ATP5F1C). Taken together, this analysis is consistent
with the hypothesis that increased mitochondrial ATP
synthesis could be a key driver of 3D anchorage-
independent growth and metastasis. See Supplemental
Figs. S1–S6.
In addition, we validated the protein expression of
ATP5F1C in female patients with a diagnosis of invasive
breast carcinoma (Luminal ER(+) BC, TNBC, HER2(+)
BC). Most notably, ATP5F1C (also known as ATP5C1)
expression is increased in lymph-node metastases, as com-
pared to the matched primary tumor samples (Fig. 1).
Moreover, ATP5F1C is highly over-expressed in distant
metastatic lesions (Fig. S6).
These findings also suggest the attractive idea that
mitochondrial ATP levels could confer a proliferative
advantage and stem-like traits in cancer cells.
Bioenergetic fractionation by flow cytometry with
BioTracker ATP-Red 1 allows the isolation of cell
sub-populations, with differing rates of proliferation
To test this “ATP hypothesis” further, we set out to identify
and purify the energetically “fittest” cancer cells from
within the total 2D cell population. For this purpose, we
chose BioTracker ATP-Red 1, a fluorescent vital dye, to
label ATP in living cancer cells (Fig. 2A).
BioTracker ATP-Red 1 is normally non-fluorescent, but
becomes fluorescent when bound to ATP, but not any other
related nucleotides or metabolites, including ADP [25].
Importantly, this ATP-biosensor exhibits a “turn-on”
fluorescence-response toward ATP, with a near sixfold
fluorescence enhancement [25]. Using fluorescence micro-
scopy, ATP-Red 1 is predominantly detected within mito-
chondria [25], the major source of cellular ATP production
(Fig. S7).
Therefore, we used ATP-Red 1 as a fluorescent probe
to energetically fractionate the cancer cell population by
flow cytometry, into ATP-high and ATP-low cell sub-
populations, which were then subjected to phenotypic
characterization. We tested various FACS gate cut-offs
for cell selection and collection but focused mainly on 5
and 10%.
Figure 2A shows an example of bioenergetic fractio-
nation with ATP-Red 1. First, we selected all live cells, in
the singlet range. Then, MCF7 cells were subjected to
metabolic fractionation by flow cytometry with ATP-Red
1, to isolate ATP-high (top 5%) and ATP-low (bottom
5%) cell subpopulations. The bulk (5%) population was
also selected for comparison purposes. Importantly, based
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on mean signal intensity, we estimate that ATP-high
MCF7 cells have approximately 15-fold higher levels of
ATP, as compared with the ATP-low population; and 2-
fold higher levels of ATP, as compared with the bulk cell
population.
The selectivity of ATP-Red 1 was independently con-
firmed, by using Cell-Titer-Glo to measure ATP levels in
cells, after flow cytometry. However, as Cell-Titer-Glo is a
luciferase-based assay, it requires cell lysis to detect intra-
cellular ATP levels and cannot be used for live-cell sorting
or imaging. After cell counting, equal numbers of single
cells were then used to evaluate their relative ATP content
by luminescence, using the Varioskan™ LUX plate reader.
Figure 2B shows that ATP-high MCF7 cells have a >15-
fold increase in ATP levels, while bulk cells showed a ~7-
fold increase ATP, all relative to the ATP-low cell
population.
Next, we assessed cell proliferation, using a continuous
real-time assay system. Figure 2C, D graphically shows the
behavior of all three cell subpopulations (ATP-low 5%,
Bulk 5%, and ATP-high 5%). Our results indicate that the
ATP-high population is approximately twofold more pro-
liferative, relative to the bulk cell population and approxi-
mately fivefold more proliferative, relative to the ATP-low
population, after 120 h of monitoring. Therefore, we con-
clude that metabolic cell fractionation with an ATP-binding
fluorescent dye reveals that high mitochondrial ATP levels
are a key determinant of MCF7 cell proliferation. Similar
results were obtained with three other breast cancer cell
lines (Fig. S7).
Metabolic analysis of 3D-mammospheres and ATP-
high MCF7 cells
To better understand the metabolism underlying 3D-
anchorage independent growth, we compared the intra-
cellular ATP levels in MCF7 cells, cultured either as 2D
monolayers or 3D mammospheres; the latter cell
population is known to be highly enriched in CSCs.
Interestingly, quantitative analysis of MCF7 cells
derived from 3D mammospheres showed an ~2.3-fold
increase in ATP levels, relative to 2D monolayer cells
(Fig. 2E). Approximately, twofold increases in both the
GSH/GSSG ratio and NADP/H levels were observed, as
well (Fig. 2E); similar results were obtained with NAD/H.
This is consistent with the idea that 3D anchorage-
independent growth may also require increased anti-
oxidant capacity.
Thus, we speculated that a subpopulation of 2D mono-
layer cells, with higher ATP levels, could have been self-
selected for their ability to undergo 3D anchorage-
independent growth. Under conditions of low attachment,
Fig. 1 ATP5F1C protein expression is increased in lymph nodal
(LN) metastases: immunostaining with monoclonal antibodies
directed against ATP5F1C. Matched formalin-fixed paraffin-
embedded (FFPE) tissue sections of the primary tumor (Left) and
lymph nodal metastases (LN; Right), from the same patients, were
subjected to immunohistochemical staining with mono-specific anti-
bodies that recognize ATP5F1C. Note that ATP5F1C expression is
increased in lymph node metastases, as compared to the matched
primary tumor samples. Three representative examples are shown,
from two luminal ER(+) breast cancer (BC) patients and one triple-
negative breast cancer (TNBC) patient. Images were acquired with a
20× objective. Scale bar= 100 µm. Please also see Supplemental Fig.
S6.
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>90% of MCF7 cells normally undergo anoikis, a specia-
lized form of apoptotic cell death. Higher ATP levels would
presumably allow CSCs to better resist the high stress of
growth in suspension, caused by the absence of cell-
substrate attachment. However, higher energy reserves
might also confer resistance to multiple stressors, resulting
in multi-drug resistance.
To test this hypothesis, we next subjected ATP-high and
ATP-low MCF7 cells to metabolic analysis for NAD/H and
two key anti-oxidants (namely, GSH and NADP/H).
Remarkably, Fig. 2F shows that ATP-high cells contain
>1.5-fold more NAD/H, >7.5-fold more NADP/H and >7-
fold more reduced glutathione (GSH/GSSG ratio), all rela-
tive to ATP-low cells. Therefore, our results are consistent
with the idea that ATP-high MCF7 cells are more energetic
and, as consequence, they fortify their anti-oxidant capacity.
High levels of antioxidants are known to be associated with
drug resistance in cancer cells, possibly suggesting a multi-
drug resistant phenotype. Therefore, we conclude that the
ATP-high MCF7 subpopulation mimics the 3D metabolic
phenotype.
ATP-high MCF7 cells are energetically hyper-active,
with increases in cancer stem cell markers,
mitochondrial mass and 3D anchorage-independent
growth
We examined “stemness” using two well-established CSC
markers, namely CD44 and ALDH activity. Figure 2G
shows that the ATP-high MCF7 cell subpopulation was
enriched nearly 4-fold in CD44 cell surface expression and
~5.5-fold in ALDH-activity when using a FACS gating cut-
off of 5%. Similar results were also obtained with Mito-
Tracker-Deep-Red, a well-established marker of mito-
chondrial mass, which revealed a threefold increase in ATP-
high MCF7 cells. We have previously shown that mito-
chondrial mass is a specific marker of stemness in CSCs
[17, 26, 27].
We next employed the 3D-mammosphere assay to
measure anchorage-independent growth, which is a func-
tional read-out for CSC activity and CSC propagation.
Interestingly, the ATP-high MCF7 cell subpopulation
showed a ninefold increase in 3D spheroid formation, when
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using a FACS gating cut-off of 5% (Fig. 2H). These data
directly support our hypothesis that ATP-high cells would
be better able to undergo 3D anchorage-independent
growth.
These findings are all consistent with the enrichment of
CSC activity. Importantly, high ALDH activity is considered
to be a biomarker of the epithelial-mesenchymal transition in
CSCs, whereas CD44 is considered to be more of an
Fig. 2 Metabolic cell fractionation with an ATP-binding fluor-
escent dye reveals that high mitochondrial ATP levels are a key
determinant of MCF7 cell proliferation, stemness, 3D anchorage-
independent growth and anti-oxidant capacity. Here, we used
staining with a vital dye, namely BioTracker ATP-Red 1, to detect
ATP levels in living cancer cells and then subjected them to flow
cytometry, to isolate the most energetic and the least energetic cancer
cells, to compare their phenotypic behavior. Please also see Supple-
mental Fig. S7. A Metabolic fractionation with Biotracker ATP-Red 1.
Experimental Procedure summarizing the key steps from live-cell
staining to the isolation of the ATP-enriched cell population, using
flow cytometry. The Biotracker ATP-Red 1 probe recognizes ATP at
the molecular level and becomes fluorescently activated, allowing the
detection of mitochondrial ATP levels. Based on mean signal inten-
sity, we estimate that ATP-high MCF7 cells have approximately 15-
fold higher levels of ATP, as compared with the ATP-low population;
and 2-fold higher levels of ATP, as compared with bulk cell popula-
tion. Data represent the mean fold increase over ATP-low 5% cells ±
SD, n= 9. One-way ANOVA, Dunnett’s multiple comparisons test,
*p < 0.01, **p < 0.001. B Validation of ATP levels after metabolic
fractionation. ATP levels in MCF7 cells were determined after flow
cytometry, using Cell-Titer-Glo. After cell counting, equal numbers of
single cells were then used to evaluate their relative ATP content by
luminescence, using the Varioskan™ LUX plate reader. Note that
ATP-high MCF7 cells showed a >15-fold increase in ATP levels,
while bulk cells showed a ~7-fold increase ATP, all relative to ATP-
low cell population. ATP-high 5% (n= 6), Bulk 5% (n= 3), ATP-low
5% (n= 6). Data represent the mean fold increase ±SD over ATP-
low 5% cells. One-way ANOVA, Dunnett’s multiple comparisons test,
*p < 0.05, ***p < 0.0005, ****p < 0.0001. C Cell proliferation. Pro-
liferation was assessed using the xCELLigence® RTCA DP instru-
ment. Cells were first sorted for ATP content, counted and seeded (1 ×
104 in common media) in RTCA DP E-Plates for real-time growth
analysis. Graphically, the three subpopulations (ATP-low 5%, Bulk
5%, ATP-high 5%) are all represented. The results indicate that the
ATP-high population is approximately twofold more proliferative,
relative to the bulk cell population and approximately 5-fold more
proliferative, relative to the ATP-low population, after 120 h. Data
represent the mean ± SD, n= 3. One-way ANOVA, Dunnett’s multi-
ple comparisons test, **p < 0.001, ***p < 0.001, ****p < 0.0001.
D Slope analysis of proliferation. Comparative slope analysis of the
three cell subpopulations. At each time point (24, 48, 72, 96, and
120 h) the slope of the ATP-high cell population, was significantly
higher compared to the other two subpopulations. Data represent
mean ± SD, n= 3. Two-way ANOVA, Tukey corrected, *p < 0.01.
E Metabolic analysis of 2D vs. 3D growth. Metabolic analysis of
MCF7 2D monolayers and 3D mammospheres. Key metabolite levels
in MCF7 cells grown as 2D adherent monolayers or 3D mammo-
spheres were compared, using Promega kits (Cell-Titer-Glo, GSH/
GSSG-Glo, NADP-NADPH-Glo, NAD-NADH-Glo). 2D monolayers
and 3D mammospheres were first dissociated into single cells with
trypsin, syringed with a 25-gauge needle and passed through a 40-µm
cell strainer. After cell counting, equal numbers of single cells were
then used to evaluate their relative luminescence content. Note that
cells derived from 3D mammospheres showed a >2-fold increase in
ATP levels; a near 2-fold increase in reduced glutathione levels; a >2-
fold increase in NADP-NADPH levels and a near 1.5-fold increase in
NAD-NADH levels, all relative to 2D monolayers. Data represent the
mean fold increase over adherent cells ±SD, n= 4. Unpaired t test,
**p < 0.005, ***p < 0.0005, ****p < 0.0001. F Metabolic analysis of
ATP-high vs. ATP low cells. Measurement of ATP, glutathione,
NADH, and NADPH were carried out in ATP-high MCF7 cells, as
compared with ATP-low MCF7 cells. Key metabolite levels were
measured using Promega kits (Cell-Titer-Glo, GSH/GSSG-Glo,
NADP-NADPH-Glo, NAD-NADH-Glo). Cells in 2D monolayers
were first stained with BioTracker ATP-Red 1 and sorted by ATP
content by flow cytometry. After cell counting, equal numbers of
single cells were then used to evaluate their relative luminescence
content. Note that ATP-high cells showed a near 25-fold increase in
ATP levels; a 6-fold increase in reduced glutathione levels; a nearly 8-
fold increase in NADP-NADPH levels and >2-fold increase in NAD-
NADH levels, all relative to ATP-low MCF7 cells. Data represent the
mean fold increase over ATP-low 5% cells ±SD, n= 4. Unpaired t
test, **p < 0.005, ***p < 0.0005. G ATP-high cells are enriched in
well-established CSC markers, and show elevated mitochondrial mass.
Stemness was first examined using two well-established CSC bio-
markers, namely CD44 expression and ALDH activity. Moreover,
mitochondrial mass was determined, in parallel, using MitoTracker
Deep-Red. Note that the ATP-high MCF7 cell subpopulation was
enriched nearly 4-fold in CD44 cell surface expression, ~5.5-fold in
ALDH activity, and nearly 3-fold in mitochondrial mass, when using a
FACS gating cut-off of 5%. These findings are consistent with the
enrichment of CSC activity. Data represent the mean fold increase
over ATP-low 5% cells ±SD, n= 3. Unpaired t test, **p < 0.005,
***p < 0.0005. H ATP-high cells show increased capacity for 3D
anchorage-independent growth. 3D anchorage-independent growth in
MCF7 cells was assessed using the 3D mammosphere assay, after
metabolic fractionation. Cells in 2D monolayers were first stained with
BioTracker ATP-Red 1 and sorted by ATP content using the SONY
SH800 flow cytometer. After cell counting, 5 × 103 cells were seeded
into poly-HEMA coated 6-well plates and counted after 5 days. Note
that ATP-high MCF7 cells showed an increased capacity to undergo
3D anchorage-independent growth, relative to bulk cells and ATP-low
MCF7 cells. ATP-high 5% (n= 6), Bulk 5% (n= 3), ATP-low 5% (n
= 6). Data represent mean fold increase over ATP-low 5% cells ±SD.
One-way ANOVA, Dunnett’s multiple comparisons test, ****p <
0.0001. Images of 3D mammospheres were acquired using the EVOS
FL Auto2 microscope. The panels represent the three sorted cell
populations. Representative Images are shown. A 4× objective was
used. Scale bar= 1000 µm. I Other fluorescent probes for anti-oxidant
capacity and pluripotency independently select for the ATP-high
population. The effectiveness of BioTracker ATP-Red 1 was com-
pared with several other fluorescent vital dyes for selecting the ATP-
high cell population. MCF7 cell 2D monolayers were harvested with
trypsin and lived-stained with a panel of five other fluorescent probes.
Then, total ATP levels were determined using Cell-Titer-Glo, fol-
lowing flow cytometry. Note that the probes for anti-oxidant capacity
(cystine-FITC and gamma-glutamyl-transpeptidase (GGT) activity)
and pluripotency, all selected for the ATP-high subpopulation. The
hypoxia probe also positively selected the ATP-high cell subpopula-
tion. However, the senescence probe (beta-galactosidase activity) did
not select for either the ATP-high or the ATP-low cell population.
Data represent the mean fold increase over Probe-low 5% cells ± SEM,
n= 3. Sidak’s multiple comparisons test, ns = not significant, *p <
0.05, ***p < 0.0005, ****p < 0.0001.
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epithelial CSC marker. So, both epithelial and mesenchymal
CSCs are significantly enriched in the ATP-high cell
subpopulation.
Fluorescent vital probes for anti-oxidant capacity
and pluripotency select for a population of ATP-
high MCF7 cells
We also compared the effectiveness of the BioTracker ATP-
Red 1 probe with several other fluorescent vital dyes for
selecting the ATP-high cell population. For this purpose,
MCF7 cell 2D monolayers were harvested with trypsin and
lived-stained with a panel of five other fluorescent Bio-
Tracker probes for (i) anti-oxidant capacity (cystine uptake
or gamma-glutamyl-transpeptidase (GGT) activity), (ii)
pluripotency, (iii) hypoxia, and (iv) senescence (beta-galac-
tosidase activity). Then, total ATP levels were determined
using Cell-Titer-Glo, immediately following flow cytometry.
Figure 2 (panel I) shows the results of this analysis.
Remarkably, the probes for anti-oxidant capacity (cystine
uptake and GGT activity), as well as pluripotency, all
selected for the ATP-high subpopulation of MCF7 cells.
However, the BioTracker probe, which directly measures
the uptake of cystine-FITC, was the most effective at
selecting the ATP-high cell population but was not as
effective as ATP-Red 1 (3-fold vs. ~20-fold). Interestingly,
high anti-oxidant capacity is known to be strictly associated
with stemness and the drug-resistance phenotype.
Surprisingly, the hypoxia probe also positively selected
the ATP-high cell subpopulation. This may be due to the
association between hypoxia and increased mitochondrial
biogenesis.
However, the senescence probe (beta-galactosidase
activity) did not select for either the ATP-high or the ATP-
low cell population.
ATP-high subpopulations of MCF7, T47D, MDA-MB-
231, and MDA-MB-468 cells all overexpress
ATP5F1C, are hyper-metabolic and show increased
3D anchorage-independent growth, as well as
elevated cell cycle progression
To examine the generality of these findings, we also prepared
ATP-high and ATP-low cell subpopulations from three other
human breast cancer cell lines, namely T47D, MDA-MB-
231, and MDA-MB-468 cells. After metabolic fractionation,
the ATP-high and ATP-low subpopulations were subjected
to Western blot analysis with a mono-specific antibody probe
that specifically recognizes ATP5F1C. Importantly,
ATP5F1C is overexpressed in the ATP-high subpopulation,
in all four cell lines tested (Fig. 3A).
Figure 3B illustrates that the ATP-high subpopulations of
all these cell lines showed characteristic increases in ATP,
as confirmed using the luciferase-based Cell-Titer-Glo
assay, with a two to threefold increase in total ATP
levels. This was also confirmed by directly imaging the
ATP-high and ATP-low cell populations, by fluorescence
microscopy (Figs. S8 and S9).
Strikingly similar results were also obtained with the 3D
spheroid assay, indicative of an increase in CSC activity and
propagation between 1.75- and 3-fold, depending on the cell
line examined (Fig. 3C).
Interestingly, in MCF7 cells, the observed increases in
ATP levels (Fig. 2A, F) were reduced to 3-fold by 24 h after
plating the ATP-high cells as a 2D monolayer, indicating
that this highly energetic phenotype is relatively transient,
consistent with a more stem-like phenotype (Fig. 3D).
Next, we used metabolic flux analysis, with the Seahorse
XFe96, to determine the energetic profiles of mitochondrial
function and glycolytic rates (Fig. 3E). Interestingly, 24 h
after cell attachment, ATP-high MCF7 cell monolayers
showed a 2-fold increase in basal respiration, a 1.5-fold
increase in maximal respiration and a 3-fold increase in
mitochondrial ATP production. Similarly, ATP-high MCF7
monolayer cells also showed a 1.5-fold increase in their
basal glycolytic rate. Therefore, ATP-high cells were clearly
more bioenergetic than their ATP-low counterparts. Quan-
titatively similar results were also obtained with MDA-MB-
231 cells (Fig. 3F).
We evaluated the proliferative capacity of the ATP-high
cell subpopulation by measuring the status of cell cycle
progression, using FACS analysis with propidium iodide to
detect DNA content. Figure 3G directly shows that the
ATP-high cell subpopulations were strikingly more pro-
liferative than the ATP-low, with a shift from the G0/G1-
phase to the S-phase and the G2/M-phase. More specifi-
cally, the G0/G1-phase was reduced from approximately
80–88% to 60–64%, while the S-phase was increased from
4–8% to 9–21%. Similarly, the G2/M-phase was increased,
from 7–12% to 17–30%. Remarkably, these clear increases
in cell cycle progression in the ATP-high cell subpopula-
tion, relative to the ATP-low subpopulation, were observed
in all four cell lines.
Importantly, quantitatively similar results were obtained
with a second-independent ATP-biosensor, recombinantly
expressed in MCF7 cells (Fig. 3H–K).
ATP-high cells show features of multi-drug
resistance: implications for understanding the
relationship between mitochondrial ATP levels,
drug resistance, and dormancy
To independently validate our results with the mammo-
sphere assay, we used a second distinct spheroid assay to
measure 3D growth, which depends instead on the self-
aggregation of single cells to form 3D spheroids. After
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self-aggregation, the average area of the spheroids derived
from MCF7, T47D, MDA-MB-231, and MDA-MB-468
cell lines was calculated, using ImageJ software. Time
points at 2, 5, and 10 days of growth are shown for the two
BioTracker ATP-Red 1 stained, sorted, subpopulation of
cells. Importantly, ATP-high cells were able to generate
much larger spheroids, as compared with ATP-low cells
(Fig. 4A). Representative images of MCF7 spheroid for-
mation are shown (Fig. 4B).
Next, we evaluated the differential sensitivity of ATP-
high and ATP-low MCF7 cell subpopulations to four
different classes of drugs, using the 3D-mammosphere
assay as a functional readout of drug resistance (Fig. 4C).
In this assay system, we first studied Tamoxifen, which
is an FDA-approved drug routinely used to clinically target
ER(+) breast cancer cells, that often leads to Tamoxifen-
resistance and treatment failure, resulting in tumor recur-
rence and distant metastasis. Interestingly, 3D-
mammosphere formation by ATP-low MCF7 cells was
remarkably sensitive to Tamoxifen treatment, resulting in a
reduction by ~40% at 1 μM and by >90% at 5 μM. In
contrast, 3D-mammosphere formation by ATP-high MCF7
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cells was strikingly resistant to Tamoxifen, as 3D-
mammosphere formation remained high at 5 μM, repre-
senting >80% of the vehicle-treated control levels. Thus,
ATP-high MCF7 cells are clearly Tamoxifen-resistant.
Validation of the multi-drug resistance phenotype was
obtained by testing several other drugs, including Dox-
ycycline (an inhibitor of mitochondrial protein translation),
DPI (an OXPHOS inhibitor), and Palbociclib (a CDK4/6
inhibitor).
Quantitatively similar results were obtained using MDA-
MB-231 cells (Fig. 4D), indicating that these ATP-high,
triple-negative, breast cancer cells were also multi-drug
resistant to Gemcitabine, Doxycycline, DPI, and
Palbociclib.
Fig. 3 ATP-high subpopulations of MCF7, T47D, MDA-MB-231,
and MDA-MB-468 cells all overexpress ATP5F1C, are hyper-
metabolic, and show increased 3D anchorage-independent growth,
as well as elevated cell cycle progression. A ATP5F1C is over-
expressed in the ATP-high cell subpopulation. After metabolic frac-
tionation, the ATP-high and ATP-low subpopulations were subjected
to Western blot analysis with a mono-specific antibody probe that
specifically recognizes ATP5F1C. Note that ATP5F1C is over-
expressed in the ATP-high subpopulation in all four cell lines tested. B
ATP levels after metabolic fractionation. The relative amount of ATP
in the ATP-high and ATP-low cell subpopulations was independently
validated using Cell-Titer-Glo. 2D monolayer cells were first stained
with BioTracker ATP-Red 1 and sorted by ATP content, using a flow
cytometer. After cell counting, equal numbers of single cells were then
used to evaluate their relative luminescence content. In this series of
experiments, we used a cut-off of 10% to define the ATP-high and
ATP-low cell populations. Note that this metabolic fractionation
scheme can be successfully applied to other breast cancer cell
lines. Data represent the mean fold increase over ATP-low 10% cells
±SD, n= 3. Unpaired t test, *p < 0.05, **p < 0.005, ***p < 0.0005.
C Mammosphere formation. Anchorage-independent growth was
quantitated using the 3D mammosphere formation assay. In this series
of experiments, we used a cut-off of 10% to define the ATP-high and
ATP-low cell populations. Cells in 2D monolayers were first stained
with BioTracker ATP-Red 1 and sorted by ATP content, using a flow
cytometer. After cell counting, 5 × 103 cells were seeded onto a poly-
HEMA coated 6-well plate and counted after 5 days. Note that the
ATP-high cell population of MCF7, T47D, MDA-MB-231, and MDA-
MB-468 cells all showed an increased capacity for 3D anchorage-
independent growth. Data represent the mean fold increase over ATP-
low 10% cells ±SD, n= 3. Unpaired t test, ***p < 0.0005, ****p <
0.0001. D ATP levels remain high, even 24 h after plating. ATP levels
in different MCF7 cell subpopulations were quantitated using Cell-
Titer-Glo analysis. After cell counting, equal numbers of single cells
were then used to evaluate their relative ATP content by luminescence
using the Varioskan™ LUX plate reader, 24 h after plating. For these
experiments, which required larger numbers of cells, we used a cut-off
of 10% to define the ATP-high and ATP-low cell populations. Note
that ATP-high cells showed a greater than threefold increase in ATP
levels, as compared to ATP-low cells. Data represent the mean fold
increase ±SD over ATP-low 10% cells, n= 3. Unpaired t test, ****p
< 0.0001. E Metabolic flux analysis of ATP-high MCF7 cells. The
OCR (oxygen consumption rate) and the ECAR (extracellular acid-
ification rate) were determined using the Seahorse XFe96, via meta-
bolic flux analysis. Note that the ATP-high MCF7 cell population
shows an increase in both basal and maximal respiration, as well as
mitochondrial ATP-production. The ATP-high MCF7 cell population
also shows an increase in glycolysis. Cell populations were analyzed
24 h after plating. Data represent the % average fold increase ±SD over
ATP-low 10% cells, n= 3. Unpaired t test, ns= not significant, *p <
0.05, **p < 0.005, ***p < 0.0005. F Metabolic flux analysis of ATP-
high MDA-MB-231 cells. The OCR (oxygen consumption rate) and
the ECAR (extracellular acidification rate) were determined using the
Seahorse XFe96, via metabolic flux analysis. Note that the ATP-high
MDA-MB-231 cell population shows an increase in both basal and
maximal respiration, as well as mitochondrial ATP-production. The
ATP-high MDA-MB-231 cell population also shows an increase in
glycolytic reserve and glycolytic reserve capacity. Cell populations
were analyzed 24 h after plating. Data represent the % average fold
increase ±SD over ATP-low 10% cells, n= 3. Unpaired t test, ns= not
significant, *p < 0.05, **p < 0.005, ***p < 0.0005. G Cell cycle pro-
gression. Note that the ATP-high cell subpopulation is hyper-pro-
liferative, with increases in cell cycle progression, showing a strong
shift away from the G0/G1-phase, toward the S-phase and the G2/M-
phase. Quantitatively similar results were obtained with MCF7, T47D,
MDA-MB-231, and MDA-MB-468 cell lines. In this series of
experiments, we used a cut-off of 10% to define the ATP-high and
ATP-low cell populations. The percentage of cells in the G0/G1, S,
and G2/M phases of the cell cycle are reported. The results are
expressed as the mean from three independent experiments, Unpaired t
test, **p < 0.005, ***p < 0.0005, ****p < 0.0001. H Tempo-ATP:
fluorescent-protein biosensor. Tempo-ATP is a fluorescent-protein
biosensor for the detection of cytosolic ATP levels. This protein bio-
sensor was stably expressed in MCF7 cells. The Tempo-ATP-
biosensor allows for the measurement of ATP levels in a real-time
fashion. As such, high GFP-fluorescent content is a reporter for high
ATP content within the cells. The protein sequence of the ATP-
binding portion of the biosensor is shown in yellow lettering, while the
while GFP-like protein sequence is shown in green. Cells were sorted
by GFP content, using flow cytometer (excitation= 517–519 nm;
emission= 535 nm). I Tempo-ATP: mammosphere formation.
Anchorage-independent growth was quantitated, using the 3D mam-
mosphere formation assay. In this series of experiments, we used a cut-
off of 10% to define the GFP-high and GFP-low cell populations. Cells
in the monolayer were first sorted for GFP content, by flow cytometry.
After cell counting, 5 × 103 cells were seeded in poly-HEMA coated 6-
well plates and counted after 5 days. Note that the number of 3D
mammospheres formed was nearly fourfold increased in GFP-high
MCF7 cells, as compared with GFP-low MCF7 cells, respectively.
Data represent the mean fold increase over GFP-low 10% cells ±SD, n
= 3. Unpaired t test, ****p < 0.0001. J Tempo-ATP: metabolic ana-
lysis. Metabolic profiling of key metabolites in GFP-high and GFP-
low TempoATP-MCF7 cells. Luminescence levels were measured in
GFP-high and GFP-low TempoATP-MCF7 cell subpopulations, using
Promega kits (Cell-Titer-Glo, GSH/GSSG-Glo, NADP-NADPH-Glo,
and NAD-NADH-Glo). Cells were sorted by GFP content, using flow
cytometry. After cell counting, equal numbers of single cells were then
used to evaluate their relative luminescence content. Note that GFP-
high MCF7 cells showed a near 2-fold increase in ATP levels; a 2-fold
increase in reduced glutathione levels; a ~1.5-fold increase in NADP-
NADPH levels; and >2-fold increase in NAD-NADH levels, all rela-
tive to GFP-low cells. Data represent the mean fold increase over GFP-
low 10% cells ±SD, n= 4. Unpaired t test, **p < 0.005, ***p <
0.0005, ****p < 0.0001. K Tempo-ATP: cell cycle progression. The
GFP-high MCF7 cell subpopulation is hyper-proliferative, with
increases in cell cycle progression, showing a strong shift away from
the G0/G1-phase, towards the S-phase and the G2/M-phase. In this
series of experiments, we used a cut-off of 10% to define the GFP-high
and GFP-low cell populations. The percentage of cells in the G0/G1,
S, and G2/M phases of the cell cycle are reported. The results are
expressed as the mean from three independent experiments, Unpaired t
test, *** p < 0.0005, ****p < 0.0001.
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Comparing BioTracker-ATP-Red 1, with well-
established markers of stemness, CD44, and ALDH-
activity: implications for dissecting dormancy
In order to directly compare the effectiveness of BioTracker
ATP-Red 1 with other CSC markers, we used a double-
labeling strategy, which was applied to both MCF7 and
MDA-MB-231 cells. More specifically, cells were double-
labeled for CD44 and ATP, using different fluorescent
channels for detection. In the case of CD44 and ATP, this
leads to 4 experimental groups: CD44-hi/ATP-hi, CD44-hi/
ATP-lo, CD44-lo/ATP-hi, and CD44-lo/ATP-lo. Optimi-
zation of the double-labeling assay, with specific FACS
gating, is presented in Fig. 4E, F.
After cell sorting, the resulting four subpopulations were
then subjected to the 3D-mammosphere assays, as a func-
tional read-out of stemness. As shown in Fig. 4G, CD44-lo/
ATP-lo cells showed the least anchorage-independent
growth, as predicted. Therefore, CD44-lo/ATP-lo cells
were chosen as the point for normalization. Remarkably,
two cell populations showed the most 3D anchorage-
independent growth: CD44-hi/ATP-hi and CD44-lo/ATP-
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hi. Therefore, high levels of ATP are the dominant deter-
minant of stemness, as compared with CD44, in both MCF7
and MDA-MB-231 cells.
If we consider only the CD44-hi population, then double-
labeling with ATP, allowed us to separate the CD44-hi
population into two subpopulations, one with high capacity
for propagation (CD44-hi/ATP-hi) and one with low capacity
for propagation (CD44-hi/ATP-lo). Therefore, the CD44-hi/
ATP-lo population clearly showed significantly less
anchorage-independent growth and may represent a more
“dormant” subpopulation of CD44(+) CSCs (Fig. S10).
Virtually identical results were also obtained by double-
labeling with ADLH-activity and ATP (Fig. 4H). As such, this
may be a powerful new approach, for sub-fractionating CSCs
into a more “active” population and a more “dormant”
population, using ATP as a secondary marker for dormancy.
Perhaps, more importantly, these results also suggest that ATP
levels may be a functional regulator of dormancy in CSCs.
Fig. 4 ATP-high cells show features of multi-drug resistance:
Implications for understanding the relationship between mito-
chondrial ATP levels, drug resistance, and dormancy. (A-B) ATP-
high cells form larger 3D spheroids. The average area of spheroids
derived from MCF7, T47D, MDA-MB-231 and MDA-MB-468 cell
lines was calculated, using ImageJ software. Note that ATP-high cells
were able to generate much larger spheroids, as compared with ATP-
low cells (A). Data represent the average fold increase ±SD over ATP-
low cells in all subpanels, n= 3. Two-way ANOVA, Tukey corrected
**p < 0.005, ***p < 0.0005, ****p < 0.0001. Images of ATP-low and
ATP-high MCF7 cellular spheroids were acquired using an EVOS FL
Auto2 microscope. Time points at 2, 5, and 10 days of growth are
shown for the two sorted subpopulation cells. Representative images
of MCF7 spheroid formation are shown (B). Note that ATP-high cells
generated larger spheroids, as compared with ATP-low cells. For
imaging, a 10× objective was used; a scale bar of 250 µm is shown. C
ATP-high MCF7 cells are drug-resistant. We evaluated the differential
sensitivity of ATP-high and ATP-low MCF7 cell subpopulations to
four different classes of drugs, using the 3D mammosphere assay as a
functional readout of drug resistance. Note that ATP-high MCF7 cells
were clearly more resistant to treatment with Doxycycline (a mitor-
ibosome inhibitor), Tamoxifen (an anti-estrogen), DPI (a mitochon-
drial OXPHOS inhibitor), and Palbociclib (a CDK4/6 inhibitor),
consistent with a multi-drug resistance phenotype, all compared with
the ATP-low 5% MCF7 cells. Data represent % average fold change
±SD over control 3D mammospheres in both panels, n= 3. One-way
ANOVA, Dunnett’s multiple comparisons test, ns= not significant,
**p < 0.005, ***p < 0.0005, ****p < 0.0001. D ATP-high MDA-MB-
231 cells are drug-resistant. We evaluated the differential sensitivity of
ATP-high and ATP-low MDA-MB-231 cell subpopulations to four
different classes of drugs, using the 3D mammosphere assay as a
functional readout of drug resistance. Note that ATP-high MDA-MB-
231 cells were clearly more resistant to treatment with Doxycycline (a
mitoribosome inhibitor), Gemcitabine (a DNA synthesis inhibitor),
DPI (a mitochondrial OXPHOS inhibitor) and Palbociclib (a CDK4/6
inhibitor), consistent with a multi-drug resistance phenotype, all
compared with the ATP-low 5% MDA-MB-231 cells. Data represent
% average fold change ±SD over control 3D mammospheres in both
panels, n= 3. One-way ANOVA, Dunnett’s multiple comparisons
test, ns= not significant, **p < 0.005, ***p < 0.0005, ****p < 0.0001.
E Comparing the effectiveness of BioTracker-ATP-Red 1, with other
well-established markers of stemness. Representative flow cytometry
profiles of BioTracker-ATP (PE-channel) and Anti-CD44 (APC-
channel) in MCF7 cells, using the SONY SH 800 cell sorter.
Unstained, BioTracker-ATP-stained, Anti-CD44-stained and Bio-
Tracker-ATP/Anti-CD44 double-labeled cell profiles are shown. These
gates were used to determine the +ve populations of cells, based on
the two different staining parameters. The labeling procedure was
applied to both MCF7 and MDA-MB-231 cell lines. The “Green gate”
detected cells with ATP-low and CD44-low content; the “Red gate”
detected the cells with ATP-high and CD44-high content. The gates
were also represented on the intensity histograms. An analogous
experimental procedure was also conducted by employing single and
double-labeling, with BioTracker-ATP (PE channel) and ALDH-
activity (APC channel). F Defining four-cell subpopulations by FACS
gating. A representative flow cytometry profile is shown, using the
SONY SH 800 cell sorter. The “Green gate” represents cells with both
ATP-low and CD44-low content; the “Orange gate” represents cells
with ATP-low and CD44-high content; the “Purple gate” represents
cells with ATP-high content and CD44-low content; the “Red gate”
represents cells with both ATP-high and CD44-high content. An
analogous strategy was used for double-labeling with BioTracker ATP
(PE channel) and ALDH-activity (APC channel). G ATP vs. CD44
cell surface expression. 3D anchorage-independent growth was mea-
sured in the different cell subpopulations, as a functional read-out of
stemness, using both MCF7 and MDA-MB-231 lines, after cell sort-
ing. Briefly, 2D-monolayers were first co-stained with both
BioTracker-ATP (PE channel) and Anti-CD44 (APC-channel) and
subjected to flow cytometry, using the SONY SH800 cell sorter. After
cell counting, 5 × 103 cells were seeded in poly-HEMA coated 6-well
plates and 3D-mammospheres were counted 5 days after plating.
Interestingly, ATP-high cells showed an increased capacity to undergo
3D anchorage-independent growth, as compared with all the cell
subpopulations. Most notably, ATP-hi/CD44-lo cells were better able
to undergo 3D anchorage-independent growth, as compared with
ATP-lo/CD44-hi cells and ATP-lo/CD44-lo cells. However, ATP-hi/
CD44-hi cells showed the most 3D anchorage-independent growth.
Data represent the average fold increase ±SD, relative to ATP-lo/
CD44-lo cells, in both panels, n= 3. One-way ANOVA, Dunnett’s
multiple comparisons test, *p < 0.05, ** p < 0.005, ****p < 0.0001. H
ATP vs. ALDH activity. 3D anchorage-independent growth was
measured in the different cell subpopulations, as a functional readout
of stemness, using both MCF7 and MDA-MB-231 lines, after cell
sorting. Briefly, 2D monolayers were first co-stained with both
BioTracker-ATP (PE channel) and for ALDH-activity (APC-channel)
and subjected to flow cytometry, using the SONY SH800 cell sorter.
After cell counting, 5 × 103 cells were seeded in poly-HEMA coated 6-
well plates and 3D mammospheres were counted 5 days after plating.
Interestingly, ATP-high cells showed an increased capacity to undergo
3D anchorage-independent growth, as compared with all the cell
subpopulations. Most notably, ATP-hi/ALDH-lo cells were better able
to undergo 3D anchorage-independent growth, as compared with
ATP-lo/ALDH-hi cells and ATP-lo/ALDH-lo cells. However, ATP-hi/
ALDH-hi cells showed the most 3D anchorage-independent growth.
Data represent the average fold increase ±SD, relative to ATP-lo/
CD44-lo cells, in both panels, n= 3. One-way ANOVA, Dunnett’s
multiple comparisons test, *p < 0.05, **p < 0.005, ****p < 0.0001. In
panel G, note that CD44-hi/ATP-hi cells showed more anchorage-
independent growth than CD44-hi/ATP-lo cells. In panel H, note that
ALDH-hi/ATP-hi cells showed more anchorage-independent growth
than ALDH-hi/ATP-lo cells. These results imply that BioTracker-ATP
can be used in combination with CSC markers, to separate CSCs into
highly proliferative and less proliferative populations. This less pro-
liferative CSC subpopulation may represent a more “dormant” CSC
phenotype. In panels A–H, a cut-off of 5% was used to define the
ATP-high and ATP-low cell populations.
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Investigating the role of mitochondrial ATP in cell
migration, invasion, and spontaneous metastasis
We hypothesized that ATP may also be an energetic bio-
marker for the process of cancer cell metastasis. For this
purpose, we focused our efforts on MDA-MB-231 cells, as
they are a well-established model for the study of cell
motility and metastasis, both in vitro and in vivo.
As a first step, we evaluated the possible co-expression
of mitochondrial markers with markers of CTCs and
metastasis, in ATP-high vs. ATP-low subpopulations.
Remarkably, mitochondrial markers from Complexes I to
V, including ATP5F1C, and HSP60 were all over-expressed
in ATP-high MDA-MB-231 cells, relative to ATP-low
MDA-MB-231 cells. In addition, three known markers of
CTCs and metastasis (VCAM-1, E-cadherin, and Ep-CAM)
were all overexpressed in ATP-high MDA-MB-231 cells
(Fig. 5A). In contrast, HIF-1α levels were increased in
ATP-low MDA-MB-231 cells.
Next, the ability of ATP-high and ATP-low subpopula-
tions of MDA-MB-231 cells to undergo cell migration and
invasion was evaluated by employing a modified Boyden
chamber assay, using Transwells. The bulk (5%) population
was also selected for comparison purposes.
Figure 5B shows the results of this analysis. Briefly,
ATP-high MDA-MB-231 cells showed a 20-40-fold
increase in their ability to undergo cell migration, rela-
tive to ATP-low cells. As expected bulk (5%) cells
showed an intermediate phenotype. Similarly, ATP-high
MDA-MB-231 cells showed a 15–60-fold increase in their
ability to undergo invasion, relative to the ATP-low cell
population (Fig. 5C). As such, ATP-high MDA-MB-231
cells may represent the pro-metastatic cell population
in vivo.
To test this hypothesis directly, we employed a well-
established in vivo metastasis assay, involving the CAM in
chicken eggs, to quantitatively measure spontaneous
metastasis (Fig. 5D).
Interestingly, Fig. 5E illustrates that ATP-high MDA-
MB-231 cells were >4.5-fold more metastatic than ATP-
low cells, derived from the same cell line. Therefore, ATP-
high MDA-MB-231 cells likely represent the pro-metastatic
CSC subpopulation (Fig. 5F). Importantly, they overexpress
ATP5F1C (Fig. 5A) and functionally generate higher levels
of mitochondrial ATP (Fig. 3F).
shRNA-targeted knockdown of ATP5F1C protein
expression inhibits ATP production, cell migration,
and 3D anchorage-independent growth
Here, we identified ATP5F1C as a clinical biomarker of
cancer metastasis (Fig. 1; Figs. S1–S6). In order to further
validate the functional relevance of ATP5F1C as a potential
therapeutic target, we next used an shRNA approach to
down-regulate ATP5F1C expression in an inducible man-
ner, by employing the Tet-On system, engineered into a
single lentiviral vector.
Figure 6A shows that, using this approach, we were able
to successfully down-regulate ATP5F1C expression in an
inducible manner, by using low levels of Doxycycline.
Importantly, by using this genetic approach to ablate
ATP5F1C expression, we demonstrated that loss of
ATP5F1C is indeed sufficient to phenotypically inhibit (i)
ATP production, (ii) cell migration, and (iii) 3D anchorage-
independent growth (Fig. 6B–E).
Targeting ATP5F1C with Bedaquiline prevents ATP
production, cell migration, 3D anchorage-
independent growth, and metastasis in vivo
Bedaquiline is an FDA-approved antibiotic that is
reserved for the treatment of multi-drug resistant tuber-
culosis (TB). Mechanistically, Bedaquiline inhibits the
mycobacterial ATP-synthase. However, more recent stu-
dies have highlighted that Bedaquiline also specifically
binds to the human mitochondrial ATP-synthase and
potently inhibits its activity [28, 29]. Ultra-structurally,
detailed cryo-EM studies have shown that the binding site
of Bedaquiline is localized to the transmembrane F0
subunit of the yeast mitochondrial ATP-synthase [29].
The F0 subunit is directly connected to the F1 subunit, via
the gamma-subunit (ATP5F1C), which functions as a
rotating central stalk [29].
Therefore, we speculated that the binding of Bedaquiline
to the transmembrane portion of mitochondrial ATP-
synthase might induce the degradation of its key binding-
partner, namely ATP5F1C. Figure 7A shows that, as pre-
dicted, the expression of ATP5F1C was indeed down-
regulated in response to Bedaquiline treatment, which was
both time- and concentration-dependent. Notably, loss of
ATP5F1C expression induced by Bedaquiline-treatment
resulted in mitochondrial ATP depletion, by up to 75%
(Fig. 7B). See also Supplemental Fig. S11.
More importantly, ATP depletion induced by Bedaqui-
line also inhibited the growth of MDA-MB-231 cells in 2D
monolayers but did not affect the growth of MCF10A cells,
a non-tumourigenic human breast epithelial cell line
(Fig. 7C). Most notably, the expression of ATP5F1C was
not affected in response to Bedaquiline treatment in
MCF10A cells (Fig. 7D). Remarkably, ATP depletion was
also not observed in MCF10A cells. See Supplemental
Fig. S12.
Moreover, ATP depletion induced by Bedaquiline
inhibited MDA-MB-231 cells from undergoing 3D
anchorage-independent growth and cell migration; simi-
larly, Bedaquiline treatment was sufficient to induce cell
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Fig. 5 ATP-high MDA-MB-231 cells are enriched in CTC markers
(EpCAM) and show increased migratory, invasive, and metastatic
potential in vivo. A Western blot analysis reveals that mitochondrial
markers and CTC markers are both upregulated in ATP-high MDA-
MB-231 cells. Note that mitochondrial markers, from Complexes I to V
(including ATP5F1C), as well as HSP60, were all over-expressed in
ATP-high MDA-MB-231 cells, relative to ATP-low MDA-MB-231
cells. In addition, three known markers of CTCs and metastasis
(VCAM-1, E-cadherin, and Ep-CAM) were all over-expressed in ATP-
high MDA-MB-231 cells. In contrast, HIF-1α was highly expressed in
ATP-low MDA-MB-231 cells. Beta-actin, Beta-tubulin, or Vinculin
were used as controls for equal protein loading. B, C ATP-high MDA-
MB-231 cells are migratory and invasive. MDA-MB-231 cells are a
well-established model for the study of cell motility and metastasis,
both in vitro and in vivo. Here, we evaluated the ability of ATP-high
and ATP-low subpopulations of MDA-MB-231 cells to undergo cell
migration and invasion, by employing a modified Boyden chamber
assay, using Transwells. The bulk (5%) population was also selected
for comparison purposes. Migration and invasion parameters were
independently quantitated, using both crystal violet staining intensity
and cell number. Representative images are shown. Scale bar=
500 μm. B Cell migration: Note that ATP-high MDA-MB-231 cells
showed a 20–40-fold increase in their ability to undergo cell migration,
relative to ATP-low cells. C Cell invasion: Similarly, ATP-high MDA-
MB-231 cells showed a 15–60-fold increase in their ability to undergo
invasion, relative to the ATP-low cell population. As expected bulk
(5%) cells showed an intermediate phenotype, for both cell migration
and invasion. One-way ANOVA, Dunnett’s multiple comparisons test,
*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001. D, E ATP-high
MDA-MB-231 cells represent the pro-metastatic cell subpopulation.
We employed a well-established in vivo metastasis assay, involving the
chorioallantoic membrane (CAM) assay in chicken eggs, to quantita-
tively measure spontaneous metastasis (D). Briefly, an inoculum of
30,000 cells (MDA-MB-231) was added onto the CAM of each egg
(day E9) and then eggs were randomized into groups. On day E18, the
lower CAM was collected to evaluate the number of metastatic cells, as
analyzed by qPCR with specific primers for Human Alu sequences.
Non-injected eggs were also evaluated in parallel, as a negative control
for specificity. Note that ATP-high MDA-MB-231 cells were ~4.5-fold
more metastatic than ATP-low cells, derived from the same cell line
(E). As a consequence, it is likely that ATP-high MDA-MB-231 cells
represent the pro-metastatic CSC subpopulation. N= 10 per group.
Unpaired t test, **p < 0.005. F ATP5F1C is a potential driver of
metastasis. Experimentally, we observe that high expression levels of
ATP5F1C are correlated with high mitochondrial ATP production and
are phenotypically associated with increased metastatic potential.
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death in MDA-MB-231 cells, presumably by acting at the
level of S-phase, to block cell cycle progression
(Fig. 7E–H). See also Supplemental Fig. S13.
In addition, ATP depletion driven by Bedaquiline
induced the expression of SQSMT1/p62, suggesting an
autophagic-related mechanism of cell death (Fig. 7I). This
was functionally confirmed by measuring LC3B levels in
MDA-MB-231 cells treated with Bedaquiline (Fig. 7J). See
also Supplemental Fig. S14.
Next, to test its in vivo activity, we used the well-
established CAM assay, employing MDA-MB-231 cells, to
measure Bedaquiline’s effects on tumor growth, sponta-
neous metastasis, and embryo toxicity (Fig. 7K). Impor-
tantly, Bedaquiline treatment was not toxic for the chick
embryos, at any of the concentrations tested in vivo
(Fig. 7L, M).
Surprisingly, Bedaquiline had no statistically significant
effect on tumor growth (Fig. 7N). In striking contrast,
Bedaquiline dose-dependently inhibited spontaneous
metastasis, by up to 84% (Fig. 7O).
Therefore, we conclude that pharmacological targeting
of the mitochondrial ATP-synthase with Bedaquiline can
selectively prevent tumor cell metastasis, by inducing
ATP-depletion, without driving systemic toxicity
(Fig. 7P).
Discussion
In this report, here we demonstrate that high mitochondrial
ATP production is a key driver of “stemness” traits and
proliferation in cancer cells. Our observations could
explain the molecular basis of metabolic heterogeneity
observed in the cancer cell population, as well as its rela-
tionship to phenotypic behaviors, such as (i) rapid cell
cycle progression and (ii) anchorage-independent growth,
which are both required for the metastatic dissemination of
CSCs in vivo.
ATP-related genes as biomarkers of tumor
recurrence and metastasis: focus on ATP5F1C
Recently, we presented evidence that treatment with a panel
of distinct anti-mitochondrial therapeutics, that target the
mitochondrial ribosome, is sufficient to potently inhibit
cancer cell metastasis, using an in vivo xenograft model
[23, 24]. These results functionally imply that high ATP
levels are critical for the process of CSC metastasis.
These findings are consistent with our current observa-
tions that ATP-high cancer cells are hyper-proliferative,
stem-like, anchorage-independent, with increases in anti-
oxidant capacity and intrinsic multi-drug resistance.
Fig. 6 shRNA-targeted knockdown of ATP5F1C protein expres-
sion inhibits mitochondrial ATP production, cell migration, and
3D anchorage-independent growth. A Inducible knock-down of
ATP5F1C. MDA-MB-231 cells were stably transduced with a lenti-
viral vector encoding an shRNA targeting ATP5F1C, in the Tet-On
system; three different shRNA constructs were tested, namely a–c.
MDA-MB-231 cells were also transduced with an shRNA-control
vector in parallel. After 48 h of shRNA-induction by treatment with
Doxycycline (10 μM), the levels of ATP5F1C were assessed by
Western blot analysis. Note that the shRNA construct c showed largest
inducible downregulation of ATP5F1C expression levels (indicated by
the RED box). As a consequence, only cells transduced with construct
c were used for further experiments, as compared with the shRNA
control, both treated with Doxycycline. B Knockdown of ATP5F1C
reduces ATP levels. Note that induced down-regulation of ATP5F1C
reduces ATP levels by ~45%, relative to the shRNA control. Unpaired
t test, **p < 0.005. C, D Knockdown of ATP5F1C inhibits cell
migration: representative images (C) and quantitation (D). Note that
induced down-regulation of ATP5F1C blocks cell migration by ~65%,
relative to the shRNA control. MDA-MB-231 cells were cultured in
presence of Doxycycline (10 μM) for 32 h and moved to Transwells
for 16 h, all in presence of Doxycycline. Representative images are
shown. Scale bar= 500 μm. Unpaired t test, **p < 0.005. E Knock-
down of ATP5F1C inhibits 3D anchorage-independent growth. Note
that induced downregulation of ATP5F1C blocks 3D mammosphere
formation by ~50%, relative to the shRNA control. Unpaired t test,
***p < 0.0005. Therefore, ATP5F1C is a key regulator of mitochon-
drial ATP-production, cell migration, and 3D mammosphere growth.
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Therefore, we speculate that the ATP-high CSCs that we
have isolated here are likely to be responsible for tumor
recurrence and metastasis in vivo.
This assertion is consistent with our bioinformatic ana-
lysis showing that ATP-related genes are closely associated
with stemness, proliferation, and metastasis, especially
ATP5F1C, which encodes the gamma subunit of the cata-
lytic core of the mitochondrial ATP synthase. Moreover, we
presented evidence that ATP5F1C is a prognostic bio-
marker of tumor recurrence and distant metastasis, as well
as a marker of treatment failure in ER(+) patients under-
going Tamoxifen therapy.
In accordance with this idea, here we observed that ATP-
high MDA-MB-231 cells showed dramatic increases in
their capacity to undergo both cell migration and invasion
in vitro, as well as spontaneous metastasis in vivo. These
findings provide independent evidence for the critical role
of mitochondrial ATP in the process of metastatic
dissemination.
Targeting ATP5F1C with Bedaquiline, an FDA-
approved drug, prevents aggressive cancer cell
behaviors, including spontaneous metastasis
Bedaquiline (a.k.a., Sirturo) is an FDA-approved antibiotic,
that is clinically used for the treatment of drug-resistant TB
(DR-TB). Originally, it was thought that Bedaquiline only
affected the mycobacterial ATP-synthase, but more recent
studies have indicated that Bedaquiline also potently inhi-
bits the yeast and human mitochondrial ATP-synthase
[28, 29].
High-resolution cryo-EM studies have shown that
Bedaquiline binds directly to the c-ring of the six trans-
membrane proteins (ATP5G1/G2/G3), that form the F0
Fig. 7 Targeting ATP5F1C with Bedaquiline prevents mitochon-
drial ATP production, cell migration, 3D anchorage-independent
growth, and metastasis in vivo. A Bedaquiline downregulates the
expression of ATP5F1C. MDA-MB-231 2D cell monolayers were
treated with Bedaquiline (0, 0.1, 1, and 10 μM) and the expression of
ATP5F1C was assessed by Western blot analysis at 4-time points (24,
48, 72, and 120 h of incubation). Note that the levels of ATP5F1C
protein expression were reduced in a sustained way, especially at
10 μM Bedaquiline, relative to vehicle-alone (DMSO) controls. B
Bedaquiline reduces mitochondrial ATP production. Note that Beda-
quiline significantly inhibited ATP production in MDA-MB-231 cells,
at a concentration of 10 μM, in a time-dependent manner, as assessed
using Biotracker ATP-Red 1, to specifically detect ATP levels. Max-
imal inhibition of 75% was observed at 120 h of treatment. Two-way
ANOVA, Sidak’s multiple comparisons test, *p < 0.05, ** p < 0.005,
***p < 0.0005, ****p < 0.0001. C Bedaquiline-induced ATP deple-
tion reduces 2D monolayer cell growth in MDA-MB-231 cells, but not
in MCF10A cells. Note that Bedaquiline effectively inhibits 2D
growth in MDA-MB-231 cells, in a time-dependent manner, at a
concentration of 10 μM. No effect was observed in MCF10A, which is
a non-tumourigenic human mammary epithelial cell line. Unpaired t
test, *p < 0.05, ** p < 0.005. D Bedaquiline does not reduce ATP5F1C
expression in MCF-10A cells. MCF-10A cell monolayers were treated
with Bedaquiline (10 μM) and the expression of ATP5F1C was
assessed by Western blot analysis at the 2-time points: 72 and 120 h of
incubation. Note that the levels of ATP5F1C protein expression were
not reduced after 72 and 120 h of treatment with 10 μM Bedaquiline,
relative to vehicle-alone (DMSO) controls. E ATP depletion inhibits
3D mammosphere formation, in a concentration-dependent manner.
Note that Bedaquiline effectively blocks 3D mammosphere formation
in MDA-MB-231 cells by ~65% at a concentration of 10 μM. One-way
ANOVA, Dunnett’s multiple comparisons test, **p < 0.005, ***p <
0.0005. F ATP depletion inhibits DNA-synthesis and induces cell
death: quantitation and representative FACS tracings. Note the twofold
reduction of MDA-MB-231 cells in the S-phase and the concomitant
twofold increase in the sub-G0–G1 population, after 120 h of treat-
ment. Two-way ANOVA, Sidak’s multiple comparisons test, ns= not
significant, ***p < 0.0005. Representative FACS tracings and Watson
analysis of the cell cycle are shown. G, H ATP-depletion inhibits cell
migration: Representative images (G) and quantitation (H). Note that
Bedaquiline blocks MDA-MB-231 cell migration by ~50%. MDA-
MB-231 cells were cultured in presence of Bedaquiline (10 μM) for
32 h and moved to Transwells for 16 h in the presence of Bedaquiline
(10 μM). Representative images are shown. Scale bar= 500 μm.
Unpaired t test, **p < 0.005. I–J ATP depletion using Bedaquiline
induces autophagy in MDA-MB-231 cells. I MDA-MB-231 2D cell
monolayers were treated with Bedaquiline (0, 0.1, 1, and 10 µM) and
the expression of SQSTM1/p62 was assessed by Western blot analysis
at 72 and 120 h. Note that the levels of SQSTM1/p62 protein
expression were increased in a sustained way, especially at 10 µM
Bedaquiline, relative to vehicle-alone (DMSO) controls. J Note that
Bedaquiline increases the LC3B content in MDA-MB-231 cells.
Autophagy Intensity was measured using the Autophagy LC3-
antibody-based Kit for Guava® Muse® Cell Analyzer by Luminex.
Cells were treated with Bedaquiline (10 µM) or vehicle alone, for 48,
72, and 120 h, and then subjected to analysis by flow cytometry. We
observed an increase of LC3B content in Bedaquiline treated cells,
based on the intensity of the signal. The analysis was conducted on
10,000 cells. Data represent the mean fold change ± SD over control
(vehicle alone; DMSO) cells, n= 3. Two-way ANOVA, Sidak’s
multiple comparisons test, **p < 0.005, ****p < 0.0001. K CAM
assay for quantitating in vivo tumor growth, metastasis and toxicity.
An inoculum of 1 × 106 MDA-MB-231 cells was added onto the CAM
of each egg (day E9) and then eggs were randomized into groups. On
day E10, tumors were detectable, and they were then treated daily for
8 days with vehicle alone (1% DMSO in PBS) or Bedaquiline. After
8 days of drug administration, on day E18 all tumors were weighed,
and the lower CAM was collected to evaluate the number of metastatic
cells, as analyzed by qPCR with specific primers for Human Alu
sequences. Before each drug administration, treatment tolerability was
evaluated by scoring the number of live and dead chicken embryos. L,
M Bedaquiline toxicity using the CAM assay: Live vs. Dead Assay
(L) and % Survival (M). Note that Bedaquiline is non-toxic, relative to
the vehicle-alone control. N ≥ 14 per group. N Tumor growth. Note
that Bedaquiline has no significant effects on tumor growth in vivo.
N ≥ 14 per group. One-way ANOVA, Dunnett’s multiple comparisons
test, ns= not significant. O Metastasis. Note that Bedaquiline pro-
gressively inhibited spontaneous metastasis in vivo, in a dose-
dependent manner, with a maximum inhibition of 84% at 120 μM.
N ≥ 7 per group. One-way ANOVA, Dunnett’s multiple comparisons
test, ns= not significant, ****p < 0.00005. P Schematic summary
diagram. Bedaquiline, an FDA-approved drug, effectively inhibited
mitochondrial ATP production and metastasis in vivo, by targeting the
gamma subunit (ATP5F1C) of the mitochondrial ATP-synthase.
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subunit of the mitochondrial ATP synthase [29]. In turn, the
c-ring of the F0 subunit is directly connected to the F1
subunit, via the gamma-subunit (ATP5F1C). The gamma-
subunit (ATP5F1C), which forms the rotary shaft of the
mitochondrial ATP-synthase, is critically involved in torque
transmission, ultimately providing the necessary mechano-
chemical energy for ATP-synthesis [30–32].
As Bedaquiline-binding significantly alters the 3D con-
formation of the c-ring, we speculated that this conforma-
tional change would induce the degradation of ATP5F1C.
In accordance with this hypothesis, we observed that
Bedaquiline induced the down-regulation of ATP5F1C
protein expression, with concomitant mitochondrial ATP
depletion, in a time- and concentration-dependent manner.
Furthermore, ATP depletion induced by Bedaquiline treat-
ment was indeed sufficient to effectively block spontaneous
metastasis in vivo, without significant toxicity in non-
tumourigenic human cells (MCF10A) in vitro or chicken
embryos in vivo.
As a consequence, we conclude that the gamma-subunit
of the mitochondrial ATP-synthase (ATP5F1C) is a new
therapeutic target, for mitigating aggressive cancer cell
behaviors, including spontaneous metastasis.
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